Clinical Trials
37 trialsAdaptive Symptom Self-Management Immunotherapy Study
University of Arizona
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Agni-01
Obsidian Therapeutics, Inc.
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
ADVICE
Filamon LTD
ANCHOR
Ankyra Therapeutics, Inc
The Florida ASCENT Study
University of Florida
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
DETERMINE
Cancer Research UK
CAPTIV-8
British Columbia Cancer Agency
EARN
Washington University School of Medicine
ABILITY-1
Medicenna Therapeutics, Inc.
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
RAPTOR
Turnstone Biologics, Corp.
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Iovance Biotherapeutics, Inc.
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
CheckMate 76U
Bristol-Myers Squibb
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
BioNTech SE
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Development of Real-time Image-guided Radiotherapy
Fox Chase Cancer Center
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
BIND Therapeutics
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Comparison of Standard of Care or Treatment on Protocol
New Mexico Cancer Research Alliance
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Hoag Memorial Hospital Presbyterian
The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients
Netherlands Open University
Study of NS-9 in Patients With Liver Metastases
NS Pharma, Inc.